Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-022765
Filing Date
2025-02-19
Accepted
2025-02-19 07:36:40
Documents
109
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K kpti-20241231.htm   iXBRL 10-K 4579790
2 EX-3.1 kpti-ex3_1.htm EX-3.1 120708
3 EX-4.2 kpti-ex4_2.htm EX-4.2 24577
4 EX-19.1 kpti-ex19_1.htm EX-19.1 92927
5 EX-21.1 kpti-ex21_1.htm EX-21.1 7221
6 EX-23.1 kpti-ex23_1.htm EX-23.1 21696
7 EX-31.1 kpti-ex31_1.htm EX-31.1 10730
8 EX-31.2 kpti-ex31_2.htm EX-31.2 10793
9 EX-32.1 kpti-ex32_1.htm EX-32.1 8480
10 GRAPHIC img95418130_0.jpg GRAPHIC 209040
11 GRAPHIC img95418130_1.jpg GRAPHIC 497052
  Complete submission text file 0000950170-25-022765.txt   19441290

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20241231.xsd EX-101.SCH 2291712
111 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20241231_htm.xml XML 3358048
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36167 | Film No.: 25637194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)